

Attorney Docket No.: 10508.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE
(DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371**

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO. PCT/DK2004/000688		INTERNATIONAL FILING DATE October 8, 2004	
APPLICANT(S)/INVENTOR(S)			
First Name	Middle Name	Family Name	
1. Leonardo 2. Carsten 3. Lars 4. Soren 5. Peter	1. 2. 3. Lehmann Hylling 4. Flensted 5. Rahbek	1. De Maria 2. Andersen 3. Christensen 4. Lassen 5. Ostergaard	
TITLE OF THE INVENTION			
Protease Variants			

1. This is a first submission of items concerning a filing under 35 U.S.C. 371.
2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
3. The US has been elected.
4. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau. The application contains the following parts:

Specification	53 Pages
Abstract	1 Pages
Sequence Listing	35 Pages
Drawings	26 Pages
Total	115 Pages

5. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made and will not be made.
6. An application data sheet is enclosed.

7. Priority of Danish application nos. PA 2003 01494 filed on October 10, 2003 and PA 2004 00333 filed March 1, 2004 is claimed under 35 U.S.C. 119(a)-(d).
8. The benefit of U.S. provisional application nos. 60/510,450 filed October 10, 2003 and 60/549,347 filed on March 2, 2004 is claimed under 35 U.S.C. 119(e).
9. An oath or declaration of the inventors is submitted herewith.
10. An Information Disclosure Statement is submitted herewith.
11. A Preliminary Amendment is submitted herewith.
12. Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same.
13. The assignee of the present application is:

Novozymes A/S
Krogshoejvej 36
DK-2880 Bagsvaerd
Denmark

Applicants request that the assignee information be included in the published patent application.

14. Direct all correspondence to Customer Number 25908.
15. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Basic Fee:	\$300.00
Examination Fee:	\$200.00
Search Fee:	\$500.00
Size Fee (\$250 for each 50 pages above 100)	\$250.00

CLAIMS FEE

Total Claims: 21 - 20 = 1 x 50 =	\$50.00
Independent Claims: 1 - 3 = 0 x 200 =	\$0.00
Total Claims Fee:	\$0.00


TOTAL NATIONAL FEE	\$1,300.00
--------------------	------------

10/574534

IAP9 Rec'd PCT/PTO 03 APR 2006

16. Please charge the required fee, estimated to be \$1,300, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,



Date: April 3, 2006

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097



4-4-64

10/574554

APR 9 Rec'd PCT/PTO 03 APR 2006

Attorney Docket No. 10508.204-US

PATENT

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: PCT/DK2004/000688

INTERNATIONAL FILING DATE: October 8, 2004

PRIORITY DATE: October 10, 2003

TITLE: Protease Variants

APPLICANT(S) FOR RO/US: De Maria et al.

EXPRESS MAIL CERTIFICATE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Express Mail Label No. **EV 611574196 US**

Date of Deposit: April 3, 2006

I hereby certify that the following attached papers or fee

1. Transmittal Letter to the DO/EO/US (in duplicate)
2. Executed Combined Declaration and Power of Attorney
3. Application Data Sheet
4. Preliminary Amendment
5. Paper Copy of Sequence Listing
6. Disk Containing Sequence Listing
7. Information Disclosure Statement
8. Form PTO/SB/08A
9. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097